Fed’s Powell opens door to potential rate cuts at Jackson Hole
Robin Swartz, the Chief Operating Officer and Chief Business Officer of Voyager Therapeutics, Inc. (NASDAQ:VYGR), recently sold 6,950 shares of the company’s common stock. The sale comes as the stock has experienced a significant decline, dropping over 25% in the past week according to InvestingPro data. The shares were sold at a weighted average price of $4.45, amounting to a total transaction value of $30,927. The sale was executed on February 11, 2025, as part of a pre-arranged plan to cover tax withholding obligations related to the vesting of restricted stock units. Following this transaction, Swartz retains ownership of 102,291 shares in the company. Despite recent market pressure, InvestingPro analysis indicates the stock is currently undervalued, with 4 analysts recently revising their earnings expectations upward. InvestingPro subscribers have access to 11 additional valuable insights about VYGR, along with comprehensive financial metrics and a detailed Pro Research Report.
In other recent news, Voyager Therapeutics has announced a shift in its gene therapy program for amyotrophic lateral sclerosis (ALS). The company is reassessing its treatment candidate VY9323 due to an off-target effect that narrowed the therapeutic window, causing a delay in the investigational new drug (IND) application previously slated for mid-2025. Despite this setback, Voyager’s cash runway is projected to extend into mid-2027. The company’s other gene therapy programs, including those for GBA1 Parkinson’s disease and Friedreich’s ataxia, remain on track with expected IND filings in 2025.
Furthermore, Voyager Therapeutics received a Buy rating from both H.C. Wainwright and Citi, with price targets set at $30.00 and $12.00 respectively. H.C. Wainwright’s endorsement followed a presentation by Voyager’s leadership team, showcasing its pipeline focused on central nervous system (CNS) disorders, while Citi’s rating reflects optimism about the company’s platform capabilities.
These are recent developments for Voyager Therapeutics, which continues to work towards transforming gene therapy for central nervous system diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.